Equity research Pila Pharma: Receives go-ahead for start of obesity trials
Equity Research
18 Aug 2026
Pila Pharma reports that it has received EMA approval to start a clinical trial to evaluate the safety and tolerability of increasing doses of XEN-D0501 versus placebo over 12 weeks of dosing in obese participants. We are encouraged that the start of clinical development in obesity at higher and potentially more clinically relevant doses now appears near, somewhat ahead of our previous assumptions
XEN-D0501 to be administered at higher, potentially more efficacious, doses
The news marks a significant step for Pila, as the new clinical trial, PP-CT04, is intended to move XEN-D0501 into a longer, higher-dose study in people living with obesity. The company states, “As we mentioned before, higher doses and longer treatment durations are considered necessary to achieve good efficacy.” Participants will be individually titrated from 4 mg twice daily to a maximum of 16 mg twice daily, with each dose level administered for 1 week, followed by an 8-week maintenance period at the highest tolerated dose. The primary endpoints are safety and tolerability, and secondary endpoints include the effect on body weight, body composition, and waist and hip circumference of 12 weeks of dosing with XEN-D0501 vs placebo.
Following screening for potentially eligible participants, we would expect the first patient to be dosed soon. The first part will function as a pilot safety cohort with 8 participants randomised 3:1 to XEN-D0501 (6 participants) or placebo (2 participants). Part 2 will comprise the remaining 38 participants, randomised 1:1 to XEN-D0501 (19 participants) or placebo (19 participants)
The release states that an agreement was entered into with a CRO to conduct Part 1, which will proceed without additional capital. However, as we discussed in the initial coverage report, we have assumed that additional capital will eventually be required for clinical development. At the same time, the approval enables a somewhat earlier start of the first part of the trial than we had previously assumed
More frequent project updates could drive the share price going forward
To conclude, we look forward to the testing of higher doses for a longer period in obese patients. Also, we expect a more frequent project news flow going forward, including the dosing of the first patient and other updates from the initial part of PP-CT04. Needless to say, any reported effects on, e.g., weight loss will be followed closely and will likely heavily influence valuation and share price. We should, however, bear in mind that the sample size is small and that, therefore, the study, like other Phase 1b/Phase 2a trials, is unlikely to provide a statistically robust efficacy readout. We will likely review our forecast and valuation assumptions in the near future (current base case valuation: SEK 2.5 per share), following the Q2 2026 report and potentially more details regarding timelines and trial planning.
Read our latest update here
Carlsquare AB. www.carlsquare.se, hereafter referred to as Carlsquare, conducts operations in Corporate Finance and Equity Research and thereby publishes information about companies, including analyses. The information has been compiled from sources that Carlsquare considers reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or similar. Opinions and conclusions expressed in the analysis are intended solely for the recipient.
The content may not be copied, reproduced, or distributed to any other person without the written consent of Carlsquare. Carlsquare shall not be liable for any direct or indirect damage caused by decisions made based on information contained in this analysis. Investments in financial instruments provide opportunities for capital appreciation and profits. All such investments are also associated with risks. The risks vary between different types of financial instruments and combinations thereof. Historical returns should not be considered as an indication of future returns.
The research is not directed at U.S. Persons (as that term is defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Companies Act 1940) and may not be distributed to such persons. Nor is the analysis aimed at such natural or legal persons where the distribution of the analysis to such persons would involve or entail a risk of violation of Swedish or foreign law or regulations
The analysis is a so-called commissioned analysis where the analysed company has signed an agreement with Carlsquare for analysis coverage. The analyses are published continuously during the contract period and against customary fixed remuneration
Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values ensuring objectivity and independence and has therefore established procedures for managing conflicts of interest
The analyst(s) do not and may not own shares in the analysed company
Niklas Elmhammer
Senior Equity Analyst
+46 70 898 39 59
niklas.elmhammer@carlsquare.com
